Genetic factors and the course of irritable bowel syndrome: associations and interactions
DOI: 10.32364/2587-6821-2023-7-5-1
O.V. Gaus, M.A. Livzan
Omsk State Medical University, Omsk, Russian Federation
Aim: to evaluate the effect of the interaction of genetic and epigenetic factors on the formation and persistence of signs concerning irritable bowel syndrome (IBS).
Patients and Methods: the study included 263 patients with IBS (189 female, 74 male, mean age — 29 [25; 35] years), including: IBS with diarrhea (n=84), IBS with constipation (n=92), mixed IBS (n=87); mild (n=110), moderate (n=99), severe (n=54) course. The control group consisted of 40 subjects comparable by gender and age. In each group, the polymorphism prevalence of candidate genes associated with IBS (COMT, DRD2, SLC6A4, LCT, FTO, TLR9), nutritional characteristics, the level of anxiety and depression, including specific gastrointestinal anxiety, life quality, cortisol content in saliva, blood serotonin, dopamine blood level, fecal zonulin.
Results: Val/Val genotype of the COMT gene, characterized by high enzyme activity, was more common among patients with IBS with diarrhea and mixed IBS (χ2=55.75, p<0.001), in severe course (χ2=32.66, p<0.001) and was associated with diarrhea (χ2=53.39, p<0.001), anxiety (χ2=20.01, p<0.001); Met/Met genotype was associated with constipation (χ2=16.09, p<0.001), abdominal pain (χ2=11.04, p=0.004) and depression (χ2=13.12, p=0.001). T/T genotype of the DRD2 gene, leading to a decrease in the density of dopamine D2 receptors, was more commonly found in patients with IBS with constipation (χ2=13.05, p=0.042) and severe course (χ2=30.37, p<0.001), and was associated with abdominal pain (χ2=42.84, p<0.001), episodes of overeating (χ2=29.05, p<0.001), sugar cravings (χ2=16.82, p=0.002) and depression (χ2=39.63, p<0.001). S/S genotype of the SLC6A4 gene, leading to a decrease in serotonin reuptake, was more common in patients with IBS with diarrhea (χ2=28.77, p<0.001), and was associated with abdominal pain (χ2=9.15, p<0.001), diarrhea (χ2=39.98, p<0.001) and anxiety (χ2=7.87, p=0.02), genotype L/L — with constipation (χ2=12.4, p=0.002). A/A genotype of the FTO gene was associated with overweight (χ2=41.33, p<0.001), episodes of overeating (χ2=31.49, p<0.001), increased consumption of added sugar (χ2=9.25, p=0.010), and cravings for sweet (χ2=26.19, p=0.001), farinaceous and confectionery products (χ2=7.85, p=0.019). CC genotype of the TLR9 gene, leading to excessive activation of TLR9, was more commonly detected in individuals with a history of acute intestinal infection (χ2=8.45, p=0.038).
Conclusion: the identified associations suggest the impact of genetic and environmental factors on the severity and nature of the IBS course.
Keywords: irritable bowel syndrome, genetic factors, epigenetic factors, catechol-O-methyltransferase, dopamine D2 receptors, serotonin reuptake transporter, fat mass and obesity-associated gene, LCT gene, toll-like receptors.
For citation: Gaus O.V., Livzan M.A. Genetic factors and the course of irritable bowel syndrome: associations and interactions. Russian Medical Inquiry. 2023;7(5):237–248 (in Russ.). DOI: 10.32364/2587-6821-2023-7-5-1.
About the authors:
Olga V. Gaus — C. Sc. (Med.), Assistant Professor of the Department of Faculty Therapy and Gastroenterology, Omsk State Medical University; 12, Lenin str., Omsk, 644099, Russian Federation; ORCID iD 0000-0001-9370-4768.
Maria A. Livzan — Dr. Sc. (Med.), Professor, Corresponding Member of the Russian Academy of Sciences, Head of the Department of Faculty Therapy and Gastroenterology, rector, Omsk State Medical University; 12, Lenin str., Omsk, 644099, Russian Federation; ORCID iD 0000-0002-6581-7017.
Contact information: Olga V. Gaus, e-mail: gaus_olga@bk.ru.
Financial Disclosure: no authors have a financial or property interest in any material or method mentioned.
There is no conflict of interests.
Received 16.02.2023.
Revised 13.03.2023.
Accepted 03.04.2023.
References
1. Chey W.D., Kurlander J., Eswaran S. Irritable bowel syndrome: a clinical review. JAMA. 2015;313(9):949–958. DOI: 10.1001/jama.2015.0954.
2. Waehrens R., Zöller B., Sundquist J. et al. Swedish national adoption study of risk of irritable bowel syndrome (IBS). BMJ Open Gastroenterol. 2017;4(1):e000156. DOI: 10.1136/bmjgast-2017-000156.
3. Saito Y.A. The role of genetics in IBS. Gastroenterol Clin North Am. 2011;40(1):45–67. DOI: 10.1016/j.gtc.2010.12.011.
4. Whorwell P.J., McCallum M., Creed F.H., Roberts C.T. Non-colonic features of irritable bowel syndrome. Gut. 1986;27(1):37–40. DOI: 10.1136/gut.27.1.37.
5. Saito Y.A., Zimmerman J.M., Harmsen W.S. et al. Irritable bowel syndrome aggregates strongly in families: a family-based case-control study. Neurogastroenterol Motil. 2008;20(7):790–797. DOI: 10.1111/j.1365-2982.2007.1077.x.
6. Saito Y.A., Petersen G.M., Larson J.J. et al. Familial aggregation of irritable bowel syndrome: a family case-control study. Am J Gastroenterol. 2010;105(4):833–841. DOI: 10.1038/ajg.2010.116.
7. Waehrens R., Ohlsson H., Sundquist J. et al. Risk of irritable bowel syndrome in first-degree, second-degree and third-degree relatives of affected individuals: a nationwide family study in Sweden. Gut. 2015;64(2):215–221. DOI: 10.1136/gutjnl-2013-305705.
8. Morris-Yates A., Talley N.J., Boyce P.M. et al. Evidence of a genetic contribution to functional bowel disorder. Am J Gastroenterol. 1998;93(8):1311–1317. DOI: 10.1111/j.1572-0241.1998.440_j.x.
9. Levy R.L., Jones K.R., Whitehead W.E. et al. Irritable bowel syndrome in twins: heredity and social learning both contribute to etiology. Gastroenterology. 2001;121(4):799–804. DOI: 10.1053/gast.2001.27995.
10. Lembo A., Zaman M., Jones M., Talley N.J. Influence of genetics on irritable bowel syndrome, gastro-oesophageal reflux and dyspepsia: a twin study. Aliment Pharmacol Ther. 2007;25(11):1343–1350. DOI: 10.1111/j.1365-2036.2007.03326.x.
11. Mohammed I., Cherkas L.F., Riley S.A. et al. Genetic influences in irritable bowel syndrome: a twin study. Am J Gastroenterol. 2005;100(6):1340–1344. DOI: 10.1111/j.1572-0241.2005.41700.x.
12. Svedberg P., Johansson S., Wallander M.A. et al. Extra-intestinal manifestations associated with irritable bowel syndrome: a twin study. Aliment Pharmacol Ther. 2002;16(5):975–983. DOI: 10.1046/j.1365-2036.2002.01254.x.
13. Henström M., D'Amato M. Genetics of irritable bowel syndrome. Mol Cell Pediatr. 2016;3(1):7. DOI: 10.1186/s40348-016-0038-6.
14. Ивашкин В.Т., Маев И.В., Шелыгин Ю.А. и др. Диагностика и лечение синдрома раздраженного кишечника (Клинические рекомендации Российской гастроэнтерологической ассоциации и Ассоциации колопроктологов России). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2021;31(5):74–95. DOI: 10.22416/1382-4376-2021-31-5-74-95. [Ivashkin V.T., Maev I.V., Shelygin Yu.A. et al. Diagnosis and Treatment of Irritable Bowel Syndrome: Clinical Recommendations of the Russian Gastroenterological Association and Association of Coloproctologists of Russia. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2021;31(5):74–95 (in Russ.)]. DOI: 10.22416/1382-4376-2021-31-5-74-95.
15. Francis C.Y., Morris J., Whorwell P.J. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther. 1997;11(2):395–402. DOI: 10.1046/j.1365-2036.1997.142318000.x.
16. Ерофеев Ю.В., Болдырева М.С., Турчанинов Д.В. и др. Организация и методика проведения социологических исследований здоровья сельского населения для информационного обеспечения системы социально-гигиенического мониторинга: Метод. рекомендации. Омск: ФГУ ЦГСЭН Омской области; 2004. [Erofeev Ju.V., Boldyreva M.S., Turchaninov D.V. et al. Organization and methods of conducting sociological studies of the health of the rural population for information support of the system of social and hygienic monitoring: Method. recommendations. Omsk: FGU CGSJeN Omsk region; 2004 (in Russ.)].
17. Zigmond A.S., Snaith R.P. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361–370. DOI: 10.1111/j.1600-0447.1983.tb09716.x.
18. Labus J.S., Bolus R., Chang L. et al. The Visceral Sensitivity Index: development and validation of a gastrointestinal symptom-specific anxiety scale. Aliment Pharmacol Ther. 2004;20(1):89–97. DOI: 10.1111/j.1365-2036.2004.02007.x.
19. Drossman D.A., Patrick D.L., Whitehead W.E. et al. Further validation of the IBS-QOL: a disease-specific quality-of-life questionnaire. Am J Gastroenterol. 2000;95(4):999–1007. DOI: 10.1111/j.1572-0241.2000.01941.x.
20. Karling P., Danielsson Å., Wikgren M. et al. The relationship between the val158met catechol-O-methyltransferase (COMT) polymorphism and irritable bowel syndrome. PLoS One. 2011;6(3):e18035. DOI: 10.1371/journal.pone.0018035.
21. Zubieta J.K., Heitzeg M.M., Smith Y.R. et al. COMT val158met genotype affects mu-opioid neurotransmitter responses to a pain stressor. Science. 2003;299(5610):1240–1243. DOI: 10.1126/science.1078546.
22. Lachman H.M., Morrow B., Shprintzen R. et al. Association of codon 108/158 catechol-O-methyltransferase gene polymorphism with the psychiatric manifestations of velo-cardio-facial syndrome. Am J Med Genet. 1996;67(5):468–472. DOI: 10.1002/(SICI)1096-8628(19960920)67:5<468::AID-AJMG5>3.0.CO;2-G.
23. Hagen K., Stovner L.J., Skorpen F. et al. The impact of the catechol-O-methyltransferase Val158Met polymorphism on survival in the general population — the HUNT study. BMC Med Genet. 2007;8:34. DOI: 10.1186/1471-2350-8-34.
24. Colzato L.S., van den Wildenberg W.P., van der Does A.J., Hommel B. Genetic markers of striatal dopamine predict individual differences in dysfunctional, but not functional impulsivity. Neuroscience. 2010;170(3):782–788. DOI: 10.1016/j.neuroscience.2010.07.050.
25. White M.J., Lawford B.R., Morris C.P., Young R.M. Interaction between DRD2 C957T polymorphism and an acute psychosocial stressor on reward-related behavioral impulsivity. Behav Genet. 2009;39(3):285–295. DOI: 10.1007/s10519-008-9255-7.
26. Hirvonen M., Laakso A., Någren K. et al. C957T polymorphism of the dopamine D2 receptor (DRD2) gene affects striatal DRD2 availability in vivo [published correction appears in Mol Psychiatry. 2005;10(9):889]. Mol Psychiatry. 2004;9(12):1060–1061. DOI: 10.1038/sj.mp.4001561.
27. Hänninen K., Katila H., Kampman O. et al. Association between the C957T polymorphism of the dopamine D2 receptor gene and schizophrenia. Neurosci Lett. 2006;407(3):195–198. DOI: 10.1016/j.neulet.2006.08.041.
28. Тихонова Т.А., Козлова И.В., Федотов Э.А. Генетические и психологические предпосылки к возникновению рефрактерного варианта синдрома раздраженного кишечника. Экспериментальная и клиническая гастроэнтерология. 2019;162(2):68–74. DOI: 10.31146/1682-8658- ecg-162-2-68-74. [Tikhonova T.A., Kozlova I.V., Fedotov E.A. Genetic and psychological prerequisites for development of refractory variant of irritable bowel syndrome. Experimental and Clinical Gastroenterology. 2019;162(2):68–74 (in Russ.)]. DOI: 10.31146/1682-8658- ecg-162-2-68-74.
29. Naitou K., Nakamori H., Shiina T. et al. Stimulation of dopamine D2-like receptors in the lumbosacral defaecation centre causes propulsive colorectal contractions in rats. J Physiol. 2016;594(15):4339–4350. DOI: 10.1113/JP272073.
30. Lesch K.P., Mössner R. Genetically driven variation in serotonin uptake: is there a link to affective spectrum, neurodevelopmental, and neurodegenerative disorders? Biol Psychiatry. 1998;44(3):179–192. DOI: 10.1016/s0006-3223(98)00121-8.
31. Stoltenberg S.F., Twitchell G.R., Hanna G.L. et al. Serotonin transporter promoter polymorphism, peripheral indexes of serotonin function, and personality measures in families with alcoholism. Am J Med Genet. 2002;114(2):230–234. DOI: 10.1002/ajmg.10187.
32. Yeo A., Boyd P., Lumsden S. et al. Association between a functional polymorphism in the serotonin transporter gene and diarrhoea predominant irritable bowel syndrome in women. Gut. 2004;53(10):1452–1458. DOI: 10.1136/gut.2003.035451.
33. Park J.M., Choi M.G., Park J.A. et al. Serotonin transporter gene polymorphism and irritable bowel syndrome. Neurogastroenterol Motil. 2006;18(11):995–1000. DOI: 10.1111/j.1365-2982.2006.00829.x.
34. Kumar S., Ranjan P., Mittal B., Ghoshal U.C. Serotonin transporter gene (SLC6A4) polymorphism in patients with irritable bowel syndrome and healthy controls. J Gastrointestin Liver Dis. 2012;21(1):31–38.
35. Zhang Z.F., Duan Z.J., Wang L.X. et al. The serotonin transporter gene polymorphism (5-HTTLPR) and irritable bowel syndrome: a meta-analysis of 25 studies. BMC Gastroenterol. 2014;14:23. DOI: 10.1186/1471-230X-14-23.
36. Mohammadi M., Tahmasebi Abdar H., Mollaei H.R. et al. Serotonin Transporter Gene (SLC6A4) Polymorphism and Mucosal Serotonin Levels in Southeastern Iranian Patients with Irritable Bowel Syndrome. Middle East J Dig Dis. 2017;9(1):26–32. DOI: 10.15171/mejdd.2016.48.
37. Sikander A., Rana S.V., Sinha S.K. et al. Serotonin transporter promoter variant: Analysis in Indian IBS patients and control population. J Clin Gastroenterol. 2009;43(10):957–961. DOI: 10.1097/MCG.0b013e3181b37e8c.
38. Berman S., Suyenobu B., Naliboff B.D. et al. Evidence for alterations in central noradrenergic signaling in irritable bowel syndrome. Neuroimage. 2012;63(4):1854–1863. DOI: 10.1016/j.neuroimage.2012.08.028.
39. Diatchenko L., Slade G.D., Nackley A.G. et al. Genetic basis for individual variations in pain perception and the development of a chronic pain condition. Hum Mol Genet. 2005;14(1):135–143. DOI: 10.1093/hmg/ddi013.
40. Gürsoy S., Erdal E., Herken H. et al. Significance of catechol-O-methyltransferase gene polymorphism in fibromyalgia syndrome. Rheumatol Int. 2003;23(3):104–107. DOI: 10.1007/s00296-002-0260-5.
41. Hagen K., Pettersen E., Stovner L.J. et al. The association between headache and Val158Met polymorphism in the catechol-O-methyltransferase gene: the HUNT Study. J Headache Pain. 2006;7(2):70–74. DOI: 10.1007/s10194-006-0281-7.
42. Smolka M.N., Bühler M., Schumann G. et al. Gene-gene effects on central processing of aversive stimuli. Mol Psychiatry. 2007;12(3):307–317. DOI: 10.1038/sj.mp.4001946.
43. Kienast T., Hariri A.R., Schlagenhauf F. et al. Dopamine in amygdala gates limbic processing of aversive stimuli in humans. Nat Neurosci. 2008;11(12):1381–1382. DOI: 10.1038/nn.2222.
44. Drabant E.M., Hariri A.R., Meyer-Lindenberg A. et al. Catechol O-methyltransferase val158met genotype and neural mechanisms related to affective arousal and regulation. Arch Gen Psychiatry. 2006;63(12):1396–1406. DOI: 10.1001/archpsyc.63.12.1396.
45. Sesack S.R., Hawrylak V.A., Matus C. et al. Dopamine axon varicosities in the prelimbic division of the rat prefrontal cortex exhibit sparse immunoreactivity for the dopamine transporter. J Neurosci. 1998;18(7):2697–2708. DOI: 10.1523/JNEUROSCI.18-07-02697.1998.
46. Sharma A., Lelic D., Brock C. et al. New technologies to investigate the brain-gut axis. World J Gastroenterol. 2009;15(2):182–191. DOI: 10.3748/wjg.15.182.
47. Mittal R., Debs L.H., Patel A.P. et al. Neurotransmitters: The Critical Modulators Regulating Gut-Brain Axis. J Cell Physiol. 2017;232(9):2359–2372. DOI: 10.1002/jcp.25518.
48. Choi Y.J., Hwang S.W., Kim N. et al. Association Between SLC6A4 Serotonin Transporter Gene Lainked Polymorphic Region and ADRA2A -1291C>G and Irritable Bowel Syndrome in Korea. J Neurogastroenterol Motil. 2014;20(3):388–399. DOI: 10.5056/jnm14020.
49. Fukudo S., Kanazawa M., Mizuno T. et al. Impact of serotonin transporter gene polymorphism on brain activation by colorectal distention. Neuroimage. 2009;47(3):946–951. DOI: 10.1016/j.neuroimage.2009.04.083.
50. Zhao T., Zhang Y., Lee J. et al. The Associations of Single Nucleotide Polymorphisms with Risk and Symptoms of Irritable Bowel Syndrome. J Pers Med. 2022;12(2):142. DOI: 10.3390/jpm12020142.
51. Camilleri M., Busciglio I., Carlson P. et al. Candidate genes and sensory functions in health and irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol. 2008;295(2):G219–G225. DOI: 10.1152/ajpgi.90202.2008.
52. Kunz M., Hennig J., Karmann A.J., Lautenbacher S. Relationship of 5-HTTLPR Polymorphism with Various Factors of Pain Processing: Subjective Experience, Motor Responsiveness and Catastrophizing. PLoS One. 2016;11(4):e0153089. DOI: 10.1371/journal.pone.0153089.
53. Domschke K., Deckert J., O'donovan M.C., Glatt S.J. Meta-analysis of COMT val158met in panic disorder: ethnic heterogeneity and gender specificity. Am J Med Genet B Neuropsychiatr Genet. 2007;144B(5):667–673. DOI: 10.1002/ajmg.b.30494.
54. Wichers M., Aguilera M., Kenis G. et al. The catechol-O-methyl transferase Val158Met polymorphism and experience of reward in the flow of daily life. Neuropsychopharmacology. 2008;33(13):3030–3036. DOI: 10.1038/sj.npp.1301520.
55. Keogh E., Ellery D., Hunt C., Hannent I. Selective attentional bias for pain-related stimuli amongst pain fearful individuals. Pain. 2001;91(1–2):91–100. DOI: 10.1016/s0304-3959(00)00422-x.
56. Geeraerts B., Vandenberghe J., Van Oudenhove L. et al. Influence of experimentally induced anxiety on gastric sensorimotor function in humans. Gastroenterology. 2005;129(5):1437–1444. DOI: 10.1053/j.gastro.2005.08.020.
57. Ohara K., Nagai M., Suzuki Y., Ohara K. Low activity allele of catechol-o-methyltransferase gene and Japanese unipolar depression. Neuroreport. 1998;9(7):1305–1308. DOI: 10.1097/00001756-199805110-00009.
58. Hettema J.M., An S.S., Bukszar J. et al. Catechol-O-methyltransferase contributes to genetic susceptibility shared among anxiety spectrum phenotypes. Biol Psychiatry. 2008;64(4):302–310. DOI: 10.1016/j.biopsych.2008.03.014.
59. Massat I., Souery D., Del-Favero J. et al. Association between COMT (Val158Met) functional polymorphism and early onset in patients with major depressive disorder in a European multicenter genetic association study. Mol Psychiatry. 2005;10(6):598–605. DOI: 10.1038/sj.mp.4001615.
60. Cusin C., Serretti A., Lattuada E. et al. Association study of MAO-A, COMT, 5-HT2A, DRD2, and DRD4 polymorphisms with illness time course in mood disorders. Am J Med Genet. 2002;114(4):380–390. DOI: 10.1002/ajmg.10358.
61. Wray N.R., James M.R., Dumenil T. et al. Association study of candidate variants of COMT with neuroticism, anxiety and depression. Am J Med Genet B Neuropsychiatr Genet. 2008;147B(7):1314–1318. DOI: 10.1002/ajmg.b.30744.
62. Oswald L.M., McCaul M., Choi L. et al. Catechol-O-methyltransferase polymorphism alters hypothalamic-pituitary-adrenal axis responses to naloxone: a preliminary report. Biol Psychiatry. 2004;55(1):102–105. DOI: 10.1016/j.biopsych.2003.07.003.
63. Jabbi M., Kema I.P., van der Pompe G. et al. Catechol-o-methyltransferase polymorphism and susceptibility to major depressive disorder modulates psychological stress response. Psychiatr Genet. 2007;17(3):183–193. DOI: 10.1097/YPG.0b013e32808374df.
64. Donofry S.D., Roecklein K.A., Wildes J.E. et al. COMT met allele differentially predicts risk versus severity of aberrant eating in a large community sample. Psychiatry Res. 2014;220(1–2):513–518. DOI: 10.1016/j.psychres.2014.08.037.
65. Caspi A., Sugden K., Moffitt T.E. et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science. 2003;301(5631):386–389. DOI: 10.1126/science.1083968.
66. Laucht M., Treutlein J., Blomeyer D. et al. Interaction between the 5-HTTLPR serotonin transporter polymorphism and environmental adversity for mood and anxiety psychopathology: evidence from a high-risk community sample of young adults. Int J Neuropsychopharmacol. 2009;12(6):737–747. DOI: 10.1017/S1461145708009875.
67. Chorbov V.M., Lobos E.A., Todorov A.A. et al. Relationship of 5-HTTLPR genotypes and depression risk in the presence of trauma in a female twin sample. Am J Med Genet B Neuropsychiatr Genet. 2007;144B(6):830–833. DOI: 10.1002/ajmg.b.30534.
68. Levey D.F., Stein M.B., Wendt F.R. et al. Bi-ancestral depression GWAS in the Million Veteran Program and meta-analysis in >1.2 million individuals highlight new therapeutic directions. Nat Neurosci. 2021;24(7):954–963. DOI: 10.1038/s41593-021-00860-2.
69. Lek F.Y., Ong H.H., Say Y.H. Association of dopamine receptor D2 gene (DRD2) Taq1 polymorphisms with eating behaviors and obesity among Chinese and Indian Malaysian university students. Asia Pac J Clin Nutr. 2018;27(3):707–717. DOI: 10.6133/apjcn.092017.09.
70. van Strien T., Snoek H.M., van der Zwaluw C.S., Engels R.C. Parental control and the dopamine D2 receptor gene (DRD2) interaction on emotional eating in adolescence. Appetite. 2010;54(2):255–261. DOI: 10.1016/j.appet.2009.11.006.
71. Amin M., Wu R., Postolache T.T., Gragnoli C. Linkage and association of novel DRD2 variants to the comorbidity of type 2 diabetes and depression. Eur Rev Med Pharmacol Sci. 2022;26(22):8370–8375. DOI: 10.26355/eurrev_202211_30372.
72. Klein T.A., Neumann J., Reuter M. et al. Genetically determined differences in learning from errors. Science. 2007;318(5856):1642–1645. DOI: 10.1126/science.1145044.
73. Li M.D., Ma J.Z., Beuten J. Progress in searching for susceptibility loci and genes for smoking-related behaviour. Clin Genet. 2004;66(5):382–392. DOI: 10.1111/j.1399-0004.2004.00302.x.
74. Kim J., Park A. A systematic review: Candidate gene and environment interaction on alcohol use and misuse among adolescents and young adults. Am J Addict. 2018;10.1111/ajad.12755. DOI: 10.1111/ajad.12755. Epub ahead of print.
75. Blum K., Baron D., Lott L. et al. In Search of Reward Deficiency Syndrome (RDS)-free Controls: The "Holy Grail" in Genetic Addiction Risk Testing. Curr Psychopharmacol. 2020;9(1):7–21. PMID: 32432025.
76. Dina C., Meyre D., Gallina S. et al. Variation in FTO contributes to childhood obesity and severe adult obesity. Nat Genet. 2007;39(6):724–726. DOI: 10.1038/ng2048.
77. Frayling T.M., Timpson N.J., Weedon M.N. et al. A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science. 2007;316(5826):889–894. DOI: 10.1126/science.1141634.
78. Mačeková S., Bernasovský I., Gabriková D. et al. Association of the FTO rs9939609 polymorphism with obesity in Roma/Gypsy population. Am J Phys Anthropol. 2012;147(1):30–34. DOI: 10.1002/ajpa.21604.
79. Cecil J.E., Tavendale R., Watt P. et al. An obesity-associated FTO gene variant and increased energy intake in children. N Engl J Med. 2008;359(24):2558–2566. DOI: 10.1056/NEJMoa0803839.
80. Wardle J., Carnell S., Haworth C.M. et al. Obesity associated genetic variation in FTO is associated with diminished satiety. J Clin Endocrinol Metab. 2008;93(9):3640–3643. DOI: 10.1210/jc.2008-0472.
81. Qi Q., Chu A.Y., Kang J.H. et al. Fried food consumption, genetic risk, and body mass index: gene-diet interaction analysis in three US cohort studies. BMJ. 2014;348:g1610. DOI: 10.1136/bmj.g1610.
82. Kilpeläinen T.O., Qi L., Brage S. et al. Physical activity attenuates the influence of FTO variants on obesity risk: a meta-analysis of 218,166 adults and 19,268 children. PLoS Med. 2011;8(11):e1001116. DOI: 10.1371/journal.pmed.1001116.
83. Sibley D.R. New insights into dopaminergic receptor function using antisense and genetically altered animals. Annu Rev Pharmacol Toxicol. 1999;39:313–341. DOI: 10.1146/annurev.pharmtox.39.1.313.
84. Hope B.T., Nye H.E., Kelz M.B. et al. Induction of a long-lasting AP-1 complex composed of altered Fos-like proteins in brain by chronic cocaine and other chronic treatments. Neuron. 1994;13(5):1235–1244. DOI: 10.1016/0896-6273(94)90061-2.
85. Di Chiara G., Bassareo V. Reward system and addiction: what dopamine does and doesn't do [published correction appears in Curr Opin Pharmacol. 2007;7(2):233]. Curr Opin Pharmacol. 2007;7(1):69–76. DOI: 10.1016/j.coph.2006.11.003.
86. Маев И.В., Трухманов А.С., Шептулин А.А. и др. Роль нарушений моторики в патогенезе функциональных расстройств желудочно-кишечного тракта и современные возможности их лечения (Резолюция Экспертного совета и обзор литературы). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2019;29(6):7–14. DOI: 10.22416/1382-4376-2019-29-6-7-14. [Maev I.V., Trukhmanov A.S., Sheptulin А.А. et al. The role of motility impairment in the pathogenesis of functional disorders of the gastrointestinal tract and modern possibilities for their treatment (Resolution of an Expert Council and literature review). Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2019;29(6):7–14 (in Russ.)]. DOI: 10.22416/1382-4376-2019-29-6-7-14.
87. Шептулин А.А., Кардашева С.С., Курбатова А.А., Ивашкин В.Т. Диетотерапия при синдроме раздраженного кишечника: спорные и нерешенные вопросы. Вопросы детской диетологии. 2020;18(4):29–35. DOI: 10.20953/1727-5784- 2020-4-29-35. [Sheptulin A.A., Kardasheva S.S., Kurbatova A.A., Ivashkin V.T. Diet therapy for irritable bowel syndrome: controversial and unresolved issues. Pediatric Nutrition. 2020;18(4):29–35 (in Russ.)]. DOI: 10.20953/1727-5784-2020-4-29-35.
88. Mattar R., Monteiro Mdo S., Villares C.A. et al. Single nucleotide polymorphism C/T(-13910), located upstream of the lactase gene, associated with adult-type hypolactasia: validation for clinical practice. Clin Biochem. 2008;41(7–8):628–630. DOI: 10.1016/j.clinbiochem.2008.01.006.
89. Fassio F., Facioni M.S., Guagnini F. Lactose Maldigestion, Malabsorption, and Intolerance: A Comprehensive Review with a Focus on Current Management and Future Perspectives. Nutrients. 2018;10(11):1599. DOI: 10.3390/nu10111599.
90. O'Keeffe M., Jansen C., Martin L. et al. Long-term impact of the low-FODMAP diet on gastrointestinal symptoms, dietary intake, patient acceptability, and healthcare utilization in irritable bowel syndrome. Neurogastroenterol Motil. 2018;30(1):10.1111/nmo.13154. DOI: 10.1111/nmo.13154.
91. Dionne J., Ford A.C., Yuan Y. et al. A Systematic Review and Meta-Analysis Evaluating the Efficacy of a Gluten-Free Diet and a Low FODMAPs Diet in Treating Symptoms of Irritable Bowel Syndrome. Am J Gastroenterol. 2018;113(9):1290–1300. DOI: 10.1038/s41395-018-0195-4.
92. Taniguchi Y., Yoshioka N., Nakata K. et al. Mechanism for maintaining homeostasis in the immune system of the intestine. Anticancer Res. 2009;29(11):4855–4860. PMID: 20032447.
93. McCusker R.H., Kelley K.W. Immune-neural connections: how the immune system's response to infectious agents influences behavior. J Exp Biol. 2013;216(Pt 1):84–98. DOI: 10.1242/jeb.073411.
94. Akira S., Takeda K. Toll-like receptor signalling. Nat Rev Immunol. 2004;4(7):499–511. DOI: 10.1038/nri1391.
95. Rakoff-Nahoum S., Paglino J., Eslami-Varzaneh F. et al. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell. 2004;118(2):229–241. DOI: 10.1016/j.cell.2004.07.002.
96. Cario E., Gerken G., Podolsky D.K. Toll-like receptor 2 controls mucosal inflammation by regulating epithelial barrier function. Gastroenterology. 2007;132(4):1359–1374. DOI: 10.1053/j.gastro.2007.02.056.
97. Abreu M.T. Toll-like receptor signalling in the intestinal epithelium: how bacterial recognition shapes intestinal function. Nat Rev Immunol. 2010;10(2):131–144. DOI: 10.1038/nri2707.
98. Carvalho A., Osório N.S., Saraiva M. et al. The C allele of rs5743836 polymorphism in the human TLR9 promoter links IL-6 and TLR9 up-regulation and confers increased B-cell proliferation. PLoS One. 2011;6(11):e28256. DOI: 10.1371/journal.pone.0028256.
99. Carvalho A., Cunha C., Almeida A.J. et al. The rs5743836 polymorphism in TLR9 confers a population-based increased risk of non-Hodgkin lymphoma. Genes Immun. 2012;13(2):197–201. DOI: 10.1038/gene.2011.59.
100. Mollaki V., Georgiadis T., Tassidou A. et al. Polymorphisms and haplotypes in TLR9 and MYD88 are associated with the development of Hodgkin's lymphoma: a candidate-gene association study. J Hum Genet. 2009;54(11):655–659. DOI: 10.1038/jhg.2009.90.
101. Lazarus R., Klimecki W.T., Raby B.A. et al. Single-nucleotide polymorphisms in the Toll-like receptor 9 gene (TLR9): frequencies, pairwise linkage disequilibrium, and haplotypes in three U.S. ethnic groups and exploratory case-control disease association studies. Genomics. 2003;81(1):85–91. DOI: 10.1016/s0888-7543(02)00022-8.
102. Török H.P., Glas J., Tonenchi L. et al. Crohn's disease is associated with a toll-like receptor-9 polymorphism. Gastroenterology. 2004;127(1):365–366. DOI: 10.1053/j.gastro.2004.05.051.
103. Villani A.C., Lemire M., Thabane M. et al. Genetic risk factors for post-infectious irritable bowel syndrome following a waterborne outbreak of gastroenteritis. Gastroenterology. 2010;138(4):1502–1513. DOI: 10.1053/j.gastro.2009.12.049.
104. Jizhong S., Qiaomin W., Chao W., Yanqing L. Corticotropin-Releasing Factor and Toll-Like Receptor Gene Expression Is Associated with Low-Grade Inflammation in Irritable Bowel Syndrome Patients with Depression. Gastroenterol Res Pract. 2016;2016:7394924. DOI: 10.1155/2016/7394924.
105. Gwee K.A., Leong Y.L., Graham C. et al. The role of psychological and biological factors in postinfective gut dysfunction. Gut. 1999;44:400–406. DOI: 10.1136/gut.44.3.400.
2. Waehrens R., Zöller B., Sundquist J. et al. Swedish national adoption study of risk of irritable bowel syndrome (IBS). BMJ Open Gastroenterol. 2017;4(1):e000156. DOI: 10.1136/bmjgast-2017-000156.
3. Saito Y.A. The role of genetics in IBS. Gastroenterol Clin North Am. 2011;40(1):45–67. DOI: 10.1016/j.gtc.2010.12.011.
4. Whorwell P.J., McCallum M., Creed F.H., Roberts C.T. Non-colonic features of irritable bowel syndrome. Gut. 1986;27(1):37–40. DOI: 10.1136/gut.27.1.37.
5. Saito Y.A., Zimmerman J.M., Harmsen W.S. et al. Irritable bowel syndrome aggregates strongly in families: a family-based case-control study. Neurogastroenterol Motil. 2008;20(7):790–797. DOI: 10.1111/j.1365-2982.2007.1077.x.
6. Saito Y.A., Petersen G.M., Larson J.J. et al. Familial aggregation of irritable bowel syndrome: a family case-control study. Am J Gastroenterol. 2010;105(4):833–841. DOI: 10.1038/ajg.2010.116.
7. Waehrens R., Ohlsson H., Sundquist J. et al. Risk of irritable bowel syndrome in first-degree, second-degree and third-degree relatives of affected individuals: a nationwide family study in Sweden. Gut. 2015;64(2):215–221. DOI: 10.1136/gutjnl-2013-305705.
8. Morris-Yates A., Talley N.J., Boyce P.M. et al. Evidence of a genetic contribution to functional bowel disorder. Am J Gastroenterol. 1998;93(8):1311–1317. DOI: 10.1111/j.1572-0241.1998.440_j.x.
9. Levy R.L., Jones K.R., Whitehead W.E. et al. Irritable bowel syndrome in twins: heredity and social learning both contribute to etiology. Gastroenterology. 2001;121(4):799–804. DOI: 10.1053/gast.2001.27995.
10. Lembo A., Zaman M., Jones M., Talley N.J. Influence of genetics on irritable bowel syndrome, gastro-oesophageal reflux and dyspepsia: a twin study. Aliment Pharmacol Ther. 2007;25(11):1343–1350. DOI: 10.1111/j.1365-2036.2007.03326.x.
11. Mohammed I., Cherkas L.F., Riley S.A. et al. Genetic influences in irritable bowel syndrome: a twin study. Am J Gastroenterol. 2005;100(6):1340–1344. DOI: 10.1111/j.1572-0241.2005.41700.x.
12. Svedberg P., Johansson S., Wallander M.A. et al. Extra-intestinal manifestations associated with irritable bowel syndrome: a twin study. Aliment Pharmacol Ther. 2002;16(5):975–983. DOI: 10.1046/j.1365-2036.2002.01254.x.
13. Henström M., D'Amato M. Genetics of irritable bowel syndrome. Mol Cell Pediatr. 2016;3(1):7. DOI: 10.1186/s40348-016-0038-6.
14. Ивашкин В.Т., Маев И.В., Шелыгин Ю.А. и др. Диагностика и лечение синдрома раздраженного кишечника (Клинические рекомендации Российской гастроэнтерологической ассоциации и Ассоциации колопроктологов России). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2021;31(5):74–95. DOI: 10.22416/1382-4376-2021-31-5-74-95. [Ivashkin V.T., Maev I.V., Shelygin Yu.A. et al. Diagnosis and Treatment of Irritable Bowel Syndrome: Clinical Recommendations of the Russian Gastroenterological Association and Association of Coloproctologists of Russia. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2021;31(5):74–95 (in Russ.)]. DOI: 10.22416/1382-4376-2021-31-5-74-95.
15. Francis C.Y., Morris J., Whorwell P.J. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther. 1997;11(2):395–402. DOI: 10.1046/j.1365-2036.1997.142318000.x.
16. Ерофеев Ю.В., Болдырева М.С., Турчанинов Д.В. и др. Организация и методика проведения социологических исследований здоровья сельского населения для информационного обеспечения системы социально-гигиенического мониторинга: Метод. рекомендации. Омск: ФГУ ЦГСЭН Омской области; 2004. [Erofeev Ju.V., Boldyreva M.S., Turchaninov D.V. et al. Organization and methods of conducting sociological studies of the health of the rural population for information support of the system of social and hygienic monitoring: Method. recommendations. Omsk: FGU CGSJeN Omsk region; 2004 (in Russ.)].
17. Zigmond A.S., Snaith R.P. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361–370. DOI: 10.1111/j.1600-0447.1983.tb09716.x.
18. Labus J.S., Bolus R., Chang L. et al. The Visceral Sensitivity Index: development and validation of a gastrointestinal symptom-specific anxiety scale. Aliment Pharmacol Ther. 2004;20(1):89–97. DOI: 10.1111/j.1365-2036.2004.02007.x.
19. Drossman D.A., Patrick D.L., Whitehead W.E. et al. Further validation of the IBS-QOL: a disease-specific quality-of-life questionnaire. Am J Gastroenterol. 2000;95(4):999–1007. DOI: 10.1111/j.1572-0241.2000.01941.x.
20. Karling P., Danielsson Å., Wikgren M. et al. The relationship between the val158met catechol-O-methyltransferase (COMT) polymorphism and irritable bowel syndrome. PLoS One. 2011;6(3):e18035. DOI: 10.1371/journal.pone.0018035.
21. Zubieta J.K., Heitzeg M.M., Smith Y.R. et al. COMT val158met genotype affects mu-opioid neurotransmitter responses to a pain stressor. Science. 2003;299(5610):1240–1243. DOI: 10.1126/science.1078546.
22. Lachman H.M., Morrow B., Shprintzen R. et al. Association of codon 108/158 catechol-O-methyltransferase gene polymorphism with the psychiatric manifestations of velo-cardio-facial syndrome. Am J Med Genet. 1996;67(5):468–472. DOI: 10.1002/(SICI)1096-8628(19960920)67:5<468::AID-AJMG5>3.0.CO;2-G.
23. Hagen K., Stovner L.J., Skorpen F. et al. The impact of the catechol-O-methyltransferase Val158Met polymorphism on survival in the general population — the HUNT study. BMC Med Genet. 2007;8:34. DOI: 10.1186/1471-2350-8-34.
24. Colzato L.S., van den Wildenberg W.P., van der Does A.J., Hommel B. Genetic markers of striatal dopamine predict individual differences in dysfunctional, but not functional impulsivity. Neuroscience. 2010;170(3):782–788. DOI: 10.1016/j.neuroscience.2010.07.050.
25. White M.J., Lawford B.R., Morris C.P., Young R.M. Interaction between DRD2 C957T polymorphism and an acute psychosocial stressor on reward-related behavioral impulsivity. Behav Genet. 2009;39(3):285–295. DOI: 10.1007/s10519-008-9255-7.
26. Hirvonen M., Laakso A., Någren K. et al. C957T polymorphism of the dopamine D2 receptor (DRD2) gene affects striatal DRD2 availability in vivo [published correction appears in Mol Psychiatry. 2005;10(9):889]. Mol Psychiatry. 2004;9(12):1060–1061. DOI: 10.1038/sj.mp.4001561.
27. Hänninen K., Katila H., Kampman O. et al. Association between the C957T polymorphism of the dopamine D2 receptor gene and schizophrenia. Neurosci Lett. 2006;407(3):195–198. DOI: 10.1016/j.neulet.2006.08.041.
28. Тихонова Т.А., Козлова И.В., Федотов Э.А. Генетические и психологические предпосылки к возникновению рефрактерного варианта синдрома раздраженного кишечника. Экспериментальная и клиническая гастроэнтерология. 2019;162(2):68–74. DOI: 10.31146/1682-8658- ecg-162-2-68-74. [Tikhonova T.A., Kozlova I.V., Fedotov E.A. Genetic and psychological prerequisites for development of refractory variant of irritable bowel syndrome. Experimental and Clinical Gastroenterology. 2019;162(2):68–74 (in Russ.)]. DOI: 10.31146/1682-8658- ecg-162-2-68-74.
29. Naitou K., Nakamori H., Shiina T. et al. Stimulation of dopamine D2-like receptors in the lumbosacral defaecation centre causes propulsive colorectal contractions in rats. J Physiol. 2016;594(15):4339–4350. DOI: 10.1113/JP272073.
30. Lesch K.P., Mössner R. Genetically driven variation in serotonin uptake: is there a link to affective spectrum, neurodevelopmental, and neurodegenerative disorders? Biol Psychiatry. 1998;44(3):179–192. DOI: 10.1016/s0006-3223(98)00121-8.
31. Stoltenberg S.F., Twitchell G.R., Hanna G.L. et al. Serotonin transporter promoter polymorphism, peripheral indexes of serotonin function, and personality measures in families with alcoholism. Am J Med Genet. 2002;114(2):230–234. DOI: 10.1002/ajmg.10187.
32. Yeo A., Boyd P., Lumsden S. et al. Association between a functional polymorphism in the serotonin transporter gene and diarrhoea predominant irritable bowel syndrome in women. Gut. 2004;53(10):1452–1458. DOI: 10.1136/gut.2003.035451.
33. Park J.M., Choi M.G., Park J.A. et al. Serotonin transporter gene polymorphism and irritable bowel syndrome. Neurogastroenterol Motil. 2006;18(11):995–1000. DOI: 10.1111/j.1365-2982.2006.00829.x.
34. Kumar S., Ranjan P., Mittal B., Ghoshal U.C. Serotonin transporter gene (SLC6A4) polymorphism in patients with irritable bowel syndrome and healthy controls. J Gastrointestin Liver Dis. 2012;21(1):31–38.
35. Zhang Z.F., Duan Z.J., Wang L.X. et al. The serotonin transporter gene polymorphism (5-HTTLPR) and irritable bowel syndrome: a meta-analysis of 25 studies. BMC Gastroenterol. 2014;14:23. DOI: 10.1186/1471-230X-14-23.
36. Mohammadi M., Tahmasebi Abdar H., Mollaei H.R. et al. Serotonin Transporter Gene (SLC6A4) Polymorphism and Mucosal Serotonin Levels in Southeastern Iranian Patients with Irritable Bowel Syndrome. Middle East J Dig Dis. 2017;9(1):26–32. DOI: 10.15171/mejdd.2016.48.
37. Sikander A., Rana S.V., Sinha S.K. et al. Serotonin transporter promoter variant: Analysis in Indian IBS patients and control population. J Clin Gastroenterol. 2009;43(10):957–961. DOI: 10.1097/MCG.0b013e3181b37e8c.
38. Berman S., Suyenobu B., Naliboff B.D. et al. Evidence for alterations in central noradrenergic signaling in irritable bowel syndrome. Neuroimage. 2012;63(4):1854–1863. DOI: 10.1016/j.neuroimage.2012.08.028.
39. Diatchenko L., Slade G.D., Nackley A.G. et al. Genetic basis for individual variations in pain perception and the development of a chronic pain condition. Hum Mol Genet. 2005;14(1):135–143. DOI: 10.1093/hmg/ddi013.
40. Gürsoy S., Erdal E., Herken H. et al. Significance of catechol-O-methyltransferase gene polymorphism in fibromyalgia syndrome. Rheumatol Int. 2003;23(3):104–107. DOI: 10.1007/s00296-002-0260-5.
41. Hagen K., Pettersen E., Stovner L.J. et al. The association between headache and Val158Met polymorphism in the catechol-O-methyltransferase gene: the HUNT Study. J Headache Pain. 2006;7(2):70–74. DOI: 10.1007/s10194-006-0281-7.
42. Smolka M.N., Bühler M., Schumann G. et al. Gene-gene effects on central processing of aversive stimuli. Mol Psychiatry. 2007;12(3):307–317. DOI: 10.1038/sj.mp.4001946.
43. Kienast T., Hariri A.R., Schlagenhauf F. et al. Dopamine in amygdala gates limbic processing of aversive stimuli in humans. Nat Neurosci. 2008;11(12):1381–1382. DOI: 10.1038/nn.2222.
44. Drabant E.M., Hariri A.R., Meyer-Lindenberg A. et al. Catechol O-methyltransferase val158met genotype and neural mechanisms related to affective arousal and regulation. Arch Gen Psychiatry. 2006;63(12):1396–1406. DOI: 10.1001/archpsyc.63.12.1396.
45. Sesack S.R., Hawrylak V.A., Matus C. et al. Dopamine axon varicosities in the prelimbic division of the rat prefrontal cortex exhibit sparse immunoreactivity for the dopamine transporter. J Neurosci. 1998;18(7):2697–2708. DOI: 10.1523/JNEUROSCI.18-07-02697.1998.
46. Sharma A., Lelic D., Brock C. et al. New technologies to investigate the brain-gut axis. World J Gastroenterol. 2009;15(2):182–191. DOI: 10.3748/wjg.15.182.
47. Mittal R., Debs L.H., Patel A.P. et al. Neurotransmitters: The Critical Modulators Regulating Gut-Brain Axis. J Cell Physiol. 2017;232(9):2359–2372. DOI: 10.1002/jcp.25518.
48. Choi Y.J., Hwang S.W., Kim N. et al. Association Between SLC6A4 Serotonin Transporter Gene Lainked Polymorphic Region and ADRA2A -1291C>G and Irritable Bowel Syndrome in Korea. J Neurogastroenterol Motil. 2014;20(3):388–399. DOI: 10.5056/jnm14020.
49. Fukudo S., Kanazawa M., Mizuno T. et al. Impact of serotonin transporter gene polymorphism on brain activation by colorectal distention. Neuroimage. 2009;47(3):946–951. DOI: 10.1016/j.neuroimage.2009.04.083.
50. Zhao T., Zhang Y., Lee J. et al. The Associations of Single Nucleotide Polymorphisms with Risk and Symptoms of Irritable Bowel Syndrome. J Pers Med. 2022;12(2):142. DOI: 10.3390/jpm12020142.
51. Camilleri M., Busciglio I., Carlson P. et al. Candidate genes and sensory functions in health and irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol. 2008;295(2):G219–G225. DOI: 10.1152/ajpgi.90202.2008.
52. Kunz M., Hennig J., Karmann A.J., Lautenbacher S. Relationship of 5-HTTLPR Polymorphism with Various Factors of Pain Processing: Subjective Experience, Motor Responsiveness and Catastrophizing. PLoS One. 2016;11(4):e0153089. DOI: 10.1371/journal.pone.0153089.
53. Domschke K., Deckert J., O'donovan M.C., Glatt S.J. Meta-analysis of COMT val158met in panic disorder: ethnic heterogeneity and gender specificity. Am J Med Genet B Neuropsychiatr Genet. 2007;144B(5):667–673. DOI: 10.1002/ajmg.b.30494.
54. Wichers M., Aguilera M., Kenis G. et al. The catechol-O-methyl transferase Val158Met polymorphism and experience of reward in the flow of daily life. Neuropsychopharmacology. 2008;33(13):3030–3036. DOI: 10.1038/sj.npp.1301520.
55. Keogh E., Ellery D., Hunt C., Hannent I. Selective attentional bias for pain-related stimuli amongst pain fearful individuals. Pain. 2001;91(1–2):91–100. DOI: 10.1016/s0304-3959(00)00422-x.
56. Geeraerts B., Vandenberghe J., Van Oudenhove L. et al. Influence of experimentally induced anxiety on gastric sensorimotor function in humans. Gastroenterology. 2005;129(5):1437–1444. DOI: 10.1053/j.gastro.2005.08.020.
57. Ohara K., Nagai M., Suzuki Y., Ohara K. Low activity allele of catechol-o-methyltransferase gene and Japanese unipolar depression. Neuroreport. 1998;9(7):1305–1308. DOI: 10.1097/00001756-199805110-00009.
58. Hettema J.M., An S.S., Bukszar J. et al. Catechol-O-methyltransferase contributes to genetic susceptibility shared among anxiety spectrum phenotypes. Biol Psychiatry. 2008;64(4):302–310. DOI: 10.1016/j.biopsych.2008.03.014.
59. Massat I., Souery D., Del-Favero J. et al. Association between COMT (Val158Met) functional polymorphism and early onset in patients with major depressive disorder in a European multicenter genetic association study. Mol Psychiatry. 2005;10(6):598–605. DOI: 10.1038/sj.mp.4001615.
60. Cusin C., Serretti A., Lattuada E. et al. Association study of MAO-A, COMT, 5-HT2A, DRD2, and DRD4 polymorphisms with illness time course in mood disorders. Am J Med Genet. 2002;114(4):380–390. DOI: 10.1002/ajmg.10358.
61. Wray N.R., James M.R., Dumenil T. et al. Association study of candidate variants of COMT with neuroticism, anxiety and depression. Am J Med Genet B Neuropsychiatr Genet. 2008;147B(7):1314–1318. DOI: 10.1002/ajmg.b.30744.
62. Oswald L.M., McCaul M., Choi L. et al. Catechol-O-methyltransferase polymorphism alters hypothalamic-pituitary-adrenal axis responses to naloxone: a preliminary report. Biol Psychiatry. 2004;55(1):102–105. DOI: 10.1016/j.biopsych.2003.07.003.
63. Jabbi M., Kema I.P., van der Pompe G. et al. Catechol-o-methyltransferase polymorphism and susceptibility to major depressive disorder modulates psychological stress response. Psychiatr Genet. 2007;17(3):183–193. DOI: 10.1097/YPG.0b013e32808374df.
64. Donofry S.D., Roecklein K.A., Wildes J.E. et al. COMT met allele differentially predicts risk versus severity of aberrant eating in a large community sample. Psychiatry Res. 2014;220(1–2):513–518. DOI: 10.1016/j.psychres.2014.08.037.
65. Caspi A., Sugden K., Moffitt T.E. et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science. 2003;301(5631):386–389. DOI: 10.1126/science.1083968.
66. Laucht M., Treutlein J., Blomeyer D. et al. Interaction between the 5-HTTLPR serotonin transporter polymorphism and environmental adversity for mood and anxiety psychopathology: evidence from a high-risk community sample of young adults. Int J Neuropsychopharmacol. 2009;12(6):737–747. DOI: 10.1017/S1461145708009875.
67. Chorbov V.M., Lobos E.A., Todorov A.A. et al. Relationship of 5-HTTLPR genotypes and depression risk in the presence of trauma in a female twin sample. Am J Med Genet B Neuropsychiatr Genet. 2007;144B(6):830–833. DOI: 10.1002/ajmg.b.30534.
68. Levey D.F., Stein M.B., Wendt F.R. et al. Bi-ancestral depression GWAS in the Million Veteran Program and meta-analysis in >1.2 million individuals highlight new therapeutic directions. Nat Neurosci. 2021;24(7):954–963. DOI: 10.1038/s41593-021-00860-2.
69. Lek F.Y., Ong H.H., Say Y.H. Association of dopamine receptor D2 gene (DRD2) Taq1 polymorphisms with eating behaviors and obesity among Chinese and Indian Malaysian university students. Asia Pac J Clin Nutr. 2018;27(3):707–717. DOI: 10.6133/apjcn.092017.09.
70. van Strien T., Snoek H.M., van der Zwaluw C.S., Engels R.C. Parental control and the dopamine D2 receptor gene (DRD2) interaction on emotional eating in adolescence. Appetite. 2010;54(2):255–261. DOI: 10.1016/j.appet.2009.11.006.
71. Amin M., Wu R., Postolache T.T., Gragnoli C. Linkage and association of novel DRD2 variants to the comorbidity of type 2 diabetes and depression. Eur Rev Med Pharmacol Sci. 2022;26(22):8370–8375. DOI: 10.26355/eurrev_202211_30372.
72. Klein T.A., Neumann J., Reuter M. et al. Genetically determined differences in learning from errors. Science. 2007;318(5856):1642–1645. DOI: 10.1126/science.1145044.
73. Li M.D., Ma J.Z., Beuten J. Progress in searching for susceptibility loci and genes for smoking-related behaviour. Clin Genet. 2004;66(5):382–392. DOI: 10.1111/j.1399-0004.2004.00302.x.
74. Kim J., Park A. A systematic review: Candidate gene and environment interaction on alcohol use and misuse among adolescents and young adults. Am J Addict. 2018;10.1111/ajad.12755. DOI: 10.1111/ajad.12755. Epub ahead of print.
75. Blum K., Baron D., Lott L. et al. In Search of Reward Deficiency Syndrome (RDS)-free Controls: The "Holy Grail" in Genetic Addiction Risk Testing. Curr Psychopharmacol. 2020;9(1):7–21. PMID: 32432025.
76. Dina C., Meyre D., Gallina S. et al. Variation in FTO contributes to childhood obesity and severe adult obesity. Nat Genet. 2007;39(6):724–726. DOI: 10.1038/ng2048.
77. Frayling T.M., Timpson N.J., Weedon M.N. et al. A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science. 2007;316(5826):889–894. DOI: 10.1126/science.1141634.
78. Mačeková S., Bernasovský I., Gabriková D. et al. Association of the FTO rs9939609 polymorphism with obesity in Roma/Gypsy population. Am J Phys Anthropol. 2012;147(1):30–34. DOI: 10.1002/ajpa.21604.
79. Cecil J.E., Tavendale R., Watt P. et al. An obesity-associated FTO gene variant and increased energy intake in children. N Engl J Med. 2008;359(24):2558–2566. DOI: 10.1056/NEJMoa0803839.
80. Wardle J., Carnell S., Haworth C.M. et al. Obesity associated genetic variation in FTO is associated with diminished satiety. J Clin Endocrinol Metab. 2008;93(9):3640–3643. DOI: 10.1210/jc.2008-0472.
81. Qi Q., Chu A.Y., Kang J.H. et al. Fried food consumption, genetic risk, and body mass index: gene-diet interaction analysis in three US cohort studies. BMJ. 2014;348:g1610. DOI: 10.1136/bmj.g1610.
82. Kilpeläinen T.O., Qi L., Brage S. et al. Physical activity attenuates the influence of FTO variants on obesity risk: a meta-analysis of 218,166 adults and 19,268 children. PLoS Med. 2011;8(11):e1001116. DOI: 10.1371/journal.pmed.1001116.
83. Sibley D.R. New insights into dopaminergic receptor function using antisense and genetically altered animals. Annu Rev Pharmacol Toxicol. 1999;39:313–341. DOI: 10.1146/annurev.pharmtox.39.1.313.
84. Hope B.T., Nye H.E., Kelz M.B. et al. Induction of a long-lasting AP-1 complex composed of altered Fos-like proteins in brain by chronic cocaine and other chronic treatments. Neuron. 1994;13(5):1235–1244. DOI: 10.1016/0896-6273(94)90061-2.
85. Di Chiara G., Bassareo V. Reward system and addiction: what dopamine does and doesn't do [published correction appears in Curr Opin Pharmacol. 2007;7(2):233]. Curr Opin Pharmacol. 2007;7(1):69–76. DOI: 10.1016/j.coph.2006.11.003.
86. Маев И.В., Трухманов А.С., Шептулин А.А. и др. Роль нарушений моторики в патогенезе функциональных расстройств желудочно-кишечного тракта и современные возможности их лечения (Резолюция Экспертного совета и обзор литературы). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2019;29(6):7–14. DOI: 10.22416/1382-4376-2019-29-6-7-14. [Maev I.V., Trukhmanov A.S., Sheptulin А.А. et al. The role of motility impairment in the pathogenesis of functional disorders of the gastrointestinal tract and modern possibilities for their treatment (Resolution of an Expert Council and literature review). Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2019;29(6):7–14 (in Russ.)]. DOI: 10.22416/1382-4376-2019-29-6-7-14.
87. Шептулин А.А., Кардашева С.С., Курбатова А.А., Ивашкин В.Т. Диетотерапия при синдроме раздраженного кишечника: спорные и нерешенные вопросы. Вопросы детской диетологии. 2020;18(4):29–35. DOI: 10.20953/1727-5784- 2020-4-29-35. [Sheptulin A.A., Kardasheva S.S., Kurbatova A.A., Ivashkin V.T. Diet therapy for irritable bowel syndrome: controversial and unresolved issues. Pediatric Nutrition. 2020;18(4):29–35 (in Russ.)]. DOI: 10.20953/1727-5784-2020-4-29-35.
88. Mattar R., Monteiro Mdo S., Villares C.A. et al. Single nucleotide polymorphism C/T(-13910), located upstream of the lactase gene, associated with adult-type hypolactasia: validation for clinical practice. Clin Biochem. 2008;41(7–8):628–630. DOI: 10.1016/j.clinbiochem.2008.01.006.
89. Fassio F., Facioni M.S., Guagnini F. Lactose Maldigestion, Malabsorption, and Intolerance: A Comprehensive Review with a Focus on Current Management and Future Perspectives. Nutrients. 2018;10(11):1599. DOI: 10.3390/nu10111599.
90. O'Keeffe M., Jansen C., Martin L. et al. Long-term impact of the low-FODMAP diet on gastrointestinal symptoms, dietary intake, patient acceptability, and healthcare utilization in irritable bowel syndrome. Neurogastroenterol Motil. 2018;30(1):10.1111/nmo.13154. DOI: 10.1111/nmo.13154.
91. Dionne J., Ford A.C., Yuan Y. et al. A Systematic Review and Meta-Analysis Evaluating the Efficacy of a Gluten-Free Diet and a Low FODMAPs Diet in Treating Symptoms of Irritable Bowel Syndrome. Am J Gastroenterol. 2018;113(9):1290–1300. DOI: 10.1038/s41395-018-0195-4.
92. Taniguchi Y., Yoshioka N., Nakata K. et al. Mechanism for maintaining homeostasis in the immune system of the intestine. Anticancer Res. 2009;29(11):4855–4860. PMID: 20032447.
93. McCusker R.H., Kelley K.W. Immune-neural connections: how the immune system's response to infectious agents influences behavior. J Exp Biol. 2013;216(Pt 1):84–98. DOI: 10.1242/jeb.073411.
94. Akira S., Takeda K. Toll-like receptor signalling. Nat Rev Immunol. 2004;4(7):499–511. DOI: 10.1038/nri1391.
95. Rakoff-Nahoum S., Paglino J., Eslami-Varzaneh F. et al. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell. 2004;118(2):229–241. DOI: 10.1016/j.cell.2004.07.002.
96. Cario E., Gerken G., Podolsky D.K. Toll-like receptor 2 controls mucosal inflammation by regulating epithelial barrier function. Gastroenterology. 2007;132(4):1359–1374. DOI: 10.1053/j.gastro.2007.02.056.
97. Abreu M.T. Toll-like receptor signalling in the intestinal epithelium: how bacterial recognition shapes intestinal function. Nat Rev Immunol. 2010;10(2):131–144. DOI: 10.1038/nri2707.
98. Carvalho A., Osório N.S., Saraiva M. et al. The C allele of rs5743836 polymorphism in the human TLR9 promoter links IL-6 and TLR9 up-regulation and confers increased B-cell proliferation. PLoS One. 2011;6(11):e28256. DOI: 10.1371/journal.pone.0028256.
99. Carvalho A., Cunha C., Almeida A.J. et al. The rs5743836 polymorphism in TLR9 confers a population-based increased risk of non-Hodgkin lymphoma. Genes Immun. 2012;13(2):197–201. DOI: 10.1038/gene.2011.59.
100. Mollaki V., Georgiadis T., Tassidou A. et al. Polymorphisms and haplotypes in TLR9 and MYD88 are associated with the development of Hodgkin's lymphoma: a candidate-gene association study. J Hum Genet. 2009;54(11):655–659. DOI: 10.1038/jhg.2009.90.
101. Lazarus R., Klimecki W.T., Raby B.A. et al. Single-nucleotide polymorphisms in the Toll-like receptor 9 gene (TLR9): frequencies, pairwise linkage disequilibrium, and haplotypes in three U.S. ethnic groups and exploratory case-control disease association studies. Genomics. 2003;81(1):85–91. DOI: 10.1016/s0888-7543(02)00022-8.
102. Török H.P., Glas J., Tonenchi L. et al. Crohn's disease is associated with a toll-like receptor-9 polymorphism. Gastroenterology. 2004;127(1):365–366. DOI: 10.1053/j.gastro.2004.05.051.
103. Villani A.C., Lemire M., Thabane M. et al. Genetic risk factors for post-infectious irritable bowel syndrome following a waterborne outbreak of gastroenteritis. Gastroenterology. 2010;138(4):1502–1513. DOI: 10.1053/j.gastro.2009.12.049.
104. Jizhong S., Qiaomin W., Chao W., Yanqing L. Corticotropin-Releasing Factor and Toll-Like Receptor Gene Expression Is Associated with Low-Grade Inflammation in Irritable Bowel Syndrome Patients with Depression. Gastroenterol Res Pract. 2016;2016:7394924. DOI: 10.1155/2016/7394924.
105. Gwee K.A., Leong Y.L., Graham C. et al. The role of psychological and biological factors in postinfective gut dysfunction. Gut. 1999;44:400–406. DOI: 10.1136/gut.44.3.400.
This work is licensed under a Creative Commons «Attribution» 4.0 License.
Previous article
Next article
